Background: The prognosis of acute decompensated heart failure (ADHF) and heart failure (HF) with atrial fibrillation (AF) has been dismal. This study was performed to investigate the clinical outcomes of catheter ablation (CA) performed in patients with concurrent ADHF and AF. Methods: We retrospectively analyzed ADHF patients with AF who were admitted to our institution from 2007 to 2017. Results: In total, 472 patients were included in this study, with a mean follow-up duration of 32.8 ± 32.9 months. The 5-year event-free rate (cardiovascular death and HF hospitalization) was 61.4%, and the 10-year event-free rate was 42.7%. A comparative analysis of the event group and control group revealed that patients in the event group were older (event group vs. control group: 72.1 ± 11.0 vs. 68.8 ± 13.4 years, p = 0.008) and had a higher proportion of Clinical Scenario 3 classifications (event group vs. control group: 24% vs. 12%, p = 0.001). Notably, patients in the event group had a lower sinus rhythm maintenance rate (event group vs. control group: 17% vs. 31%, p < 0.001) and CA rate (event group vs. control group: 9% vs. 21%, p = 0.003). The CA group had a higher event-free rate than the non-CA group, and this trend persisted even after matching the patients’ backgrounds (log-rank test: p < 0.001). Conclusions: Patients presenting with AF at the onset of ADHF showed a poor prognosis, whereas CA demonstrated potential for improving the prognosis for some of these patients.
Background: Wearable cardioverter-defibrillators (WCDs) are equipped with the TRENDS remote-monitoring system, enabling continuous assessment of arrhythmias, physiological parameters, and patient-reported outcomes. This study evaluated the clinical utility of TRENDS-integrated WCD management and compared it with a historical control. Methods: We prospectively analyzed 36 consecutive patients who received a WCD with TRENDS between 2019 and 2024 and compared them with 30 historical controls treated before the implementation of TRENDS. Results: The WCD indications were heart failure as primary prevention (64%) and acute coronary syndrome with ventricular arrhythmias (28%). Among 18 patients who met the criteria for an implantable cardioverter-defibrillator (ICD), including 1 patient with WCD shock, 9 ultimately underwent ICD implantation. The mean daily WCD wear-time was 21.3 h and did not differ significantly from that of the historical control. The response rate to health-related questionnaires was 89%. TRENDS detected symptom exacerbation in 31% of patients, weight gain in 19% of patients, and missed medication in 19% of patients. Daily step-count was significantly lower in patients with ICD indications than in those without (5012 ± 2980 steps vs. 7977 ± 3584 steps, p = 0.01). TRENDS data also aided in initiating anticoagulation therapy and optimizing beta-blocker therapy. Conclusions: TRENDS provided clinically actionable physiologic and patient-reported information that supported individualized cardiovascular management.